|
Post by prcgorman2 on Jun 26, 2024 16:26:03 GMT -5
I’m sorry gorman but evidence is strong that Wall Street shares my view, but I know you will always want to believe otherwise. We can agree to disagree 👍🏼 I think a 5x increase in share price achieved by a newly minted CEO for a company that was very heavily shorted, nearly into non-existence, with less than 1 quarters worth of operating capital (cash) when the new CEO took over to accomplish profitability within 7 years and completely debt free (depending on when MNKD can be above $5.21 for 20 out of 30 trading days) is strong evidence Wall Street agrees with me. I anticipate we''ll see additional significant share price appreciation under the current CEO, and in far less than 7 more years, but each investor must do their own due diligence and arrive at their own conclusions.
|
|
|
Post by cretin11 on Jun 26, 2024 16:45:13 GMT -5
You can cherry pick if you wish, but anyone could easily point out what happened after MC was appointed CCO and tasked with commercializing Afrezza. Where was share price then, and why did it decline so much after that, those are relevant questions if one wants to thusly live in the past. He doesn’t deserve all the blame for it, just like simplistically saying “5x” is similarly misleading. But none of it changes the opinion I stated, as I suspect you realize (albeit you don’t agree).
|
|
|
Post by prcgorman2 on Jun 26, 2024 16:52:14 GMT -5
I'm not sure what the average tenure of a CEO is in a failing company being asked to re-launch a product without a salesforce or a marketing team for a product that a major BP renegged on, but I wouldn't have guessed 7 years. I also wouldn't have predicted the one-product company would not only still be in business but arguably thriving 7 years later.
|
|
|
Post by cretin11 on Jun 26, 2024 17:34:18 GMT -5
Martine not only saved MNKD from a difficult circumstance, she also prolonged MC’s job. If that’s the deal we had to make, it was probably worth it. And his tenure has allowed us to accumulate shares at a valuation lower than we all believe is warranted, so that’s a positive spin on it. 😄
|
|
|
Post by prcgorman2 on Jun 26, 2024 18:32:45 GMT -5
You don’t give Martine enough credit. She’s shrewd, not charitable. Ask the folks at LQDA.
|
|
|
Post by peppy on Jun 26, 2024 18:41:17 GMT -5
Martine not only saved MNKD from a difficult circumstance, she also prolonged MC’s job. If that’s the deal we had to make, it was probably worth it. And his tenure has allowed us to accumulate shares at a valuation lower than we all believe is warranted, so that’s a positive spin on it. 😄 Consider Martine did not just save MNKD. Consider, Martine sought out a deal with MNKD to have UTHR make more money. UTHR was trading at 96 dollars when Martine made the deal. UTHR made a new all time high today. schrts.co/vxGqSpCx$321.75 closing at $318.95. UTHR's Revenue and EPS has gone up. Trials for label expansion. UTHR has a sales force. Side note, is Martine growing lungs.... tissue and organ in her lab? Chat GPT4 said, "Immunosuppressants: Medications like cyclosporine, used in preventing transplant rejection, could be considered for inhalation, especially for lung transplants, to deliver the drug directly to the target organ."
|
|
|
Post by cretin11 on Jun 26, 2024 19:33:23 GMT -5
Martine not only saved MNKD from a difficult circumstance, she also prolonged MC’s job. If that’s the deal we had to make, it was probably worth it. And his tenure has allowed us to accumulate shares at a valuation lower than we all believe is warranted, so that’s a positive spin on it. 😄 Consider Martine did not just save MNKD. Consider, Martine sought out a deal with MNKD to have UTHR make more money. UTHR was trading at 96 dollars when Martine made the deal. UTHR made a new all time high today. $321.75 closing at $318.95. Exactly, peppy gets it. Interestingly, Zealand Pharma also sought out a deal with MNKD. When that negotiation closed it was trading at $11. Two years later Zealand is also at an all time high, over $124.
|
|
|
Post by prcgorman2 on Jun 27, 2024 6:18:43 GMT -5
Agree. Peppy gets that Martine made a wize choice to partner with MannKind and Mike Castagna brokered the deal. You seem to be the one laboring under a fantasy that Martine swooped in like an angel to save MannKind out of love for the deceased company namesake. Get real.
Mike’s been in the seat day in and day out for 7 years and added a doctorate pharma to his Wharton MBA while he was at it. I don’t care who you are, that is work. His career progression from working his way through college in a pharmacy to CEO of a $1B+ pipeline company, and his work ethic speak for themselves and we long investors are benefitting from it.
|
|
|
Post by cretin11 on Jun 27, 2024 12:36:07 GMT -5
I guess when you feel insecure in your logic you have to fabricate stuff, as you did with “fantasy that Martine swooped in like an angel to save MannKind out of love for the deceased company namesake.”
Those are your words not mine. It’s also known as a strawman argument, i.e. changing the debate. Martine (as peppy said) made a smart move to benefit HER company. Mike did the right thing by saying yes (we agree there). UTHR is now hitting all time highs. Zealand also made a smart move to benefit their company, and now Zealand is hitting all time highs.
That’s two deals Mike made, both counterparts are hitting all time highs now. What would you say is the third most significant deal he’s made for MNKD in all these years? I’m not even sure what that would be. Perhaps you can now grasp why some aren’t as confident as you are in our CEO’s negotiation skills. Though I can’t blame him at all for UTHR, it was his best move IMO as he had to know playing hardball with Martine would’ve meant the deal could go to LQDA. Thankfully he said yes to that one. I wish we had more of a sample size to judge him on, but deals have been scant with him.
Though I view MC objectively and not emotionally like some do, I am still pulling for him as long as he’s what we have. In the meantime it’s a great trading stock with so much potential when in the right hands.
|
|
|
Post by prcgorman2 on Jun 27, 2024 13:24:01 GMT -5
I don't know why you won't credit MC as having engineered the deal with UTHR by joining LQDA and one other company in developing a product that competed with Tyvaso which went off patent. UTHR (Martine) tried to buy both LQDA and the other competitor that wasn't MNKD and instead chose to partner with MNKD. MNKD had successfully proven they could load treprostinil on Technosphere (called TreT) and completed a Phase 1 trial. The deal was good for MNKD because they got badly needed revenue, and it was good for UTHR because it eliminated another potential competitor. The negotiation to purchase LQDA failed and the what followed has been very entertaining for this board. If Martine had simply chosen to ignore MNKD, it could be argued 100% of the revenue UTHR is enjoying from their flagship product, Tyvaso DPI, would instead be enjoyed by MNKD shareholders. It was smart business for both companies and it is disingenuous to ignore the facts.
|
|
|
Post by cretin11 on Jun 27, 2024 14:35:38 GMT -5
That's not an unreasonable take (though i don't follow this: "If Martine had simply chosen to ignore MNKD, it could be argued 100% of the revenue UTHR is enjoying from their flagship product, Tyvaso DPI, would instead be enjoyed by MNKD shareholders.")
And it doesn't negate any of the points I've made. Ultimately I'm a fan and believer of TechnoSphere including Afrezza. As for who our CEO is, objectivity is what dictates my sentiment. I want us to have a strong person in that role, whether mc can evelove into that or someone else. We have one success (TreT) in these eight years so it could be worse (zero). Of course I believe it could've been much better but we can't change the past. Anyone who doesn't agree perhaps doesn't have the same level of belief in the technology. Averaging down and options premiums have worked out quite well for some of us, we have learned how this stock moves under current leadership. Please don't mistake my words as me being a hater or upset because I'm not. It's an investment, not a family member's health or something of that importance. I still believe we will get to a higher valuation over time hence I stay long in this despite any shortcomings of leadership. We are priced for poor performance and my bet is we can at least perform at a mediocre level and therefore see share price rise (though taking much longer than anyone here ever fathomed it would).
|
|
|
Post by hellodolly on Jun 27, 2024 14:39:15 GMT -5
This is a debate that doesn't really matter anymore. Both sides have merit. I'm just glad we are not in the trash heap of failed biotechs.
|
|
|
Post by prcgorman2 on Jun 27, 2024 15:27:58 GMT -5
That's not an unreasonable take (though i don't follow this: "If Martine had simply chosen to ignore MNKD, it could be argued 100% of the revenue UTHR is enjoying from their flagship product, Tyvaso DPI, would instead be enjoyed by MNKD shareholders.") And it doesn't negate any of the points I've made. Ultimately I'm a fan and believer of TechnoSphere including Afrezza. As for who our CEO is, objectivity is what dictates my sentiment. I want us to have a strong person in that role, whether mc can evelove into that or someone else. We have one success (TreT) in these eight years so it could be worse (zero). Of course I believe it could've been much better but we can't change the past. Anyone who doesn't agree perhaps doesn't have the same level of belief in the technology. Averaging down and options premiums have worked out quite well for some of us, we have learned how this stock moves under current leadership. Please don't mistake my words as me being a hater or upset because I'm not. It's an investment, not a family member's health or something of that importance. I still believe we will get to a higher valuation over time hence I stay long in this despite any shortcomings of leadership. We are priced for poor performance and my bet is we can at least perform at a mediocre level and therefore see share price rise (though taking much longer than anyone here ever fathomed it would). Not sure how to estimate who did the most work to get TreT (nka Tyvaso DPI) approved by the FDA, but a bunch was MNKD. Could MNKD have managed Phase 2 and 3 trials and marketed TreT? Well, that's what they're queuing up to do with nintedanib but that's now not then. Anyway, that's why I said "arguably". Think about it. You don't do a Phase 1 trial for fun. The implication is you're going to continue as long as you're successful, and ultimately the team of UTHR and MNKD were (and are) successful.
The reason I bristle at your persistent attempts to cast Dr. Castagna as incompetent is because its both disrespectful and unfair. Hopefully his efforts will someday be recognized in a way that even you will admit he's done a good job (assuming you're capable of admitting that).
|
|
|
Post by cretin11 on Jun 27, 2024 16:10:27 GMT -5
I am and always have been capable of that if (but only if) warranted. I share your desire for that to happen one day, better late than never and I've been patient for this long! And i'll point out once again your penchant for inventing words to spin things when you debate - this time you say "incompetent" which I've never said. Mediocre, yes (and I'm not the only one who has said that, one of your revered posters here has also). Using a strawman argument does not reflect well and is not persuasive, just fyi for the future. Play it straight if you believe your position as i think you do. But for now I point to hellodolly's post above and wholeheartedly endorse that sentiment. GLTATL!
|
|
|
Post by Clement on Jul 8, 2024 7:53:47 GMT -5
Total Tyvaso (both T-neb and T-DPI) revenues in 2023 in Q1 and Q2:
Q1 2023 $238.4M Q2 2023 $318.9M
That's an increase of ~$80M from Q1 to Q2. In % that's 33.8% growth from Q1 to Q2 last year.
|
|